These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 26318692

  • 21. B-cell depleting agents for ANCA vasculitides: a new therapeutic approach.
    Gómez-Puerta JA, Quintana LF, Stone JH, Ramos-Casals M, Bosch X.
    Autoimmun Rev; 2012 Jul; 11(9):646-52. PubMed ID: 22146313
    [Abstract] [Full Text] [Related]

  • 22. Long-term effects of rituximab added to cyclophosphamide in refractory patients with vasculitis.
    Roccatello D, Sciascia S, Rossi D, Alpa M, Naretto C, Russo A, Menegatti E, Baldovino S.
    Am J Nephrol; 2011 Jul; 34(2):175-80. PubMed ID: 21757891
    [Abstract] [Full Text] [Related]

  • 23. Rituximab in relapsing or refractory ANCA-associated vasculitis: a case series of 16 patients.
    Wendt M, Gunnarsson I, Bratt J, Bruchfeld A.
    Scand J Rheumatol; 2012 Mar; 41(2):116-9. PubMed ID: 22118245
    [Abstract] [Full Text] [Related]

  • 24. Long-term follow-up of different refractory systemic vasculitides treated with rituximab.
    Rees F, Yazdani R, Lanyon P.
    Clin Rheumatol; 2011 Sep; 30(9):1241-5. PubMed ID: 21523362
    [Abstract] [Full Text] [Related]

  • 25. Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Is There Still a Role for Cyclophosphamide?
    Sattui SE, Spiera RF.
    Rheum Dis Clin North Am; 2019 Aug; 45(3):379-398. PubMed ID: 31277751
    [Abstract] [Full Text] [Related]

  • 26. Is rituximab effective for induction of remission in ANCA-associated vasculitis?
    Rain C, Yáñez T, Rada G.
    Medwave; 2015 Aug 13; 15 Suppl 2():e6209. PubMed ID: 26335502
    [Abstract] [Full Text] [Related]

  • 27. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab.
    Eriksson P.
    J Intern Med; 2005 Jun 13; 257(6):540-8. PubMed ID: 15910558
    [Abstract] [Full Text] [Related]

  • 28. The role of rituximab in the treatment of ANCA-associated vasculitides (AAV).
    Daikeler T, Kistler AD, Martin PY, Vogt B, Huynh-Do U.
    Swiss Med Wkly; 2015 Jun 13; 145():w14103. PubMed ID: 25658140
    [Abstract] [Full Text] [Related]

  • 29. Association of ANCA-associated vasculitis-rheumatoid arthritis overlap syndrome in four patients: rituximab may be the right choice?
    Szilasi M, Mátyus J, File I, Szücs G, Rákóczi E, Pfliegler G, Szabó Z, Végh E, Szekanecz Z.
    Autoimmunity; 2012 Jun 13; 45(4):304-9. PubMed ID: 22443800
    [Abstract] [Full Text] [Related]

  • 30. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.
    Timlin H, Lee SM, Manno RL, Seo P, Geetha D.
    Semin Arthritis Rheum; 2015 Aug 13; 45(1):67-9. PubMed ID: 25796088
    [Abstract] [Full Text] [Related]

  • 31. Pro: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab?
    Specks U.
    Nephrol Dial Transplant; 2015 Jul 13; 30(7):1083-7. PubMed ID: 25999375
    [Abstract] [Full Text] [Related]

  • 32. Rituximab for anti-neutrophil cytoplasmic antibodies-associated vasculitis: experience of a single center and systematic review of non-randomized studies.
    Ayan G, Esatoglu SN, Hatemi G, Ugurlu S, Seyahi E, Melikoglu M, Fresko I, Ozdogan H, Yurdakul S, Hamuryudan V.
    Rheumatol Int; 2018 Apr 13; 38(4):607-622. PubMed ID: 29322343
    [Abstract] [Full Text] [Related]

  • 33. Rituximab in ANCA-Associated Vasculitis.
    Hassan RI, Gaffo AL.
    Curr Rheumatol Rep; 2017 Feb 13; 19(2):6. PubMed ID: 28155022
    [Abstract] [Full Text] [Related]

  • 34. Gleaning relapse risk from B cell phenotype: decreased CD5+ B cells portend a shorter time to relapse after B cell depletion in patients with ANCA-associated vasculitis.
    Bunch DO, Mendoza CE, Aybar LT, Kotzen ES, Colby KR, Hu Y, Hogan SL, Poulton CJ, Schmitz JL, Falk RJ, Nachman PH, Pendergraft WF, McGregor JG.
    Ann Rheum Dis; 2015 Sep 13; 74(9):1784-6. PubMed ID: 25934841
    [No Abstract] [Full Text] [Related]

  • 35. Rituximab treatment of ANCA-associated vasculitis.
    Raffray L, Guillevin L.
    Expert Opin Biol Ther; 2020 Aug 13; 20(8):899-910. PubMed ID: 32293192
    [Abstract] [Full Text] [Related]

  • 36. Rituximab as maintenance therapy for ANCA associated vasculitis: how, when and why?
    Alba MA, Flores-Suárez LF.
    Reumatol Clin; 2016 Aug 13; 12(1):39-46. PubMed ID: 26255570
    [Abstract] [Full Text] [Related]

  • 37. Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis: a NICE single technology appraisal.
    Latimer NR, Carroll C, Wong R, Tappenden P, Venning MC, Luqmani R.
    Pharmacoeconomics; 2014 Dec 13; 32(12):1171-83. PubMed ID: 25059204
    [Abstract] [Full Text] [Related]

  • 38. Unmet Needs in the Pathogenesis and Treatment of Vasculitides.
    Muratore F, Pazzola G, Soriano A, Pipitone N, Croci S, Bonacini M, Boiardi L, Salvarani C.
    Clin Rev Allergy Immunol; 2018 Apr 13; 54(2):244-260. PubMed ID: 28895041
    [Abstract] [Full Text] [Related]

  • 39. Rituximab in ANCA-associated vasculitis: fad or fact?
    Fervenza FC.
    Nephron Clin Pract; 2011 Apr 13; 118(2):c182-8; discussion c188. PubMed ID: 21160229
    [Abstract] [Full Text] [Related]

  • 40. L51. From immunosuppression to selective treatments: the benefit-risk ratio.
    Guillevin L.
    Presse Med; 2013 Apr 13; 42(4 Pt 2):641-3. PubMed ID: 23453210
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.